Shoreline Biosciences, Inc. completed the acquisition of Editas Medicine iNK cell franchise, EDIT-202 and certain related manufacturing technology from Editas Medicine, Inc.
January 30, 2023
Share
Shoreline Biosciences, Inc. entered into a definitive agreement to acquire Editas Medicine iNK cell franchise, EDIT-202 and certain related manufacturing technology from Editas Medicine, Inc. on January 19, 2023. Shoreline will pay Editas Medicine an unknown upfront payment at the close of the transaction. Additionally, Editas Medicine is eligible to receive future development and commercial milestone and royalty payments for each of the iNK programs and for future programs engineered with the gene editing technologies Under the terms of the agreement, Shoreline will obtain an exclusive license to Editas Medicineâs interest in SLEEK gene editing knock-in technology for use in Shorelineâs iNKplatform and for oncology in its iMACs platform, and on a non-exclusive basis for iMACs in other indications. Shoreline will also receive a non-exclusive license for the use of Editas Medicineâs engineered AsCas12a enzyme. As part of the transaction, Shoreline will acquire EDIT-202, Editas Medicineâs preclinical multiplexed edited iNK cell medicine for the potential treatment of solid tumors, as well as an additional iNK program under development and certain related manufacturing technologies. The acquisition of Editas Medicine wholly owned oncology assets by Shoreline is part of Editas Medicineâs strategic portfolio reprioritization, including its focus on the development of in vivo gene edited medicines. Evercore Group LLC acted as financial advisor to Editas Medicine on the transaction.
Shoreline Biosciences, Inc. completed the acquisition of Editas Medicine iNK cell franchise, EDIT-202 and certain related manufacturing technology from Editas Medicine, Inc. in January 2023.
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).
Shoreline Biosciences, Inc. completed the acquisition of Editas Medicine iNK cell franchise, EDIT-202 and certain related manufacturing technology from Editas Medicine, Inc.